Sun, Sep 21, 2014, 7:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exact Sciences Corporation Message Board

  • crapnebula crapnebula Oct 11, 2012 2:34 PM Flag

    Over Priced is Over Priced

    Sure, I like this company too. The area where we disagree and where I think you guys fail big time is in your constant pumping, you fail to see the truth; this company is up 2000% in 5 years in anticipation of an event that is binary in nature and 1 to 3 months from being illuminated. Still there are many hurdles to cross. FDA, Funding and Medical Community and Public embrace. That is not to say these issues won't be resolved favorably, moreover, that they still exist and all things considered like the GOOD side of the story; have already been priced in - and IMO, priced too far in. One thing people here BLINDLY accept as fact is that there is no competing technology, that EXAS won't have any competition. Call me stupid, while I call you arrogant, but I have seen many such upsets i my years of trading stocks. ANYTHING is possible including the "better mousetrap" and of course, the spector of FRAUD committed by seemingly upright people. Not accusing, just stating the obvious: NO ONE TRULY KNOWS. I will not tell you at what price I am a buyer as I don't wish to influence others to jump in ahead of me, but I will say this: IT IS LEAPS AND BOUNDS BELOW 11.00 per share.

    Sentiment: Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thank Golly for the Ignore Button.... Your couple of days of misinformed spewing has wasted too much of my time.

      Sentiment: Strong Buy

    • excluding unpredictable market declines, what company events in the next 12-24 months might bring this into your price range? just curious.

    • The market disagrees with you. Shake your fist at the sun if you like, but it will still be there tomorrow, and EXAS will still be trading above $10.

      "ANYTHING is possible including the "better mousetrap" and of course, the spector of FRAUD committed by seemingly upright people. Not accusing, just stating the obvious: NO ONE TRULY KNOWS."

      With this, you imply that the science has not been proven out. You missed the paper trail of peer-reviewed studies by Exact and independent research centers showing the evolution of stool-based DNA detection of CRC. Through that evolution, it makes sense that the test sensitivity is where it is today. Good luck with your FUD campaign, message board retribution, or whatever it is that motivates you to post beyond your expertise.

    • "One thing people here BLINDLY accept as fact is that there is no competing technology, that EXAS won't have any competition. Call me stupid, while I call you arrogant, but I have seen many such upsets i my years of trading stocks."

      You obviously have a very poor knowledge base regarding EXAS and colon cancer screening.
      No one is accepting anything "blindly" as you claim. EXAS has the exclusive rights to DNA extraction from stool all the way out to Year 2030. You obviously are not aware of this. Furthermore, there is no other NON-INVASIVE screening test on the market that screens for Pre-Cancers.

      I would strongly suggest that you learn more about the Company, before opening up your mouth and "inserting your foot".

      :)

      • 1 Reply to sailingaway82
      • "EXAS has the exclusive rights to DNA extraction from stool all the way out to Year 2030. "
        LOL! Surely you can not be this naive?@!#!! Do you actually believe that there are no other unpublished (and unpatented) methodologies out there right now that analyze DNA from stool? It's a joke right?. This company's patent claims to DNA analysis ONLY cover their particular methodology. To make the claim that ALL DNA analysis from stool belongs to EXAS would be as stupid as claiming that all DNA analysis of oh, I dont know, AMNIOTIC FLUID, OR HAIR remain under the sole ownership of a single entity is a FAR stretch indeed. Especially in light of what's been taking place in today's courtrooms. Did you read about a Judge overturning Apples ban on Samsung's Galaxy III phones today? Apple's tanked 70 points in a week - now we know why.
        LOL No, Im sorry but this is the most ridiculous claim I have read yet. My goodness you pumpers go to some pretty extreme lengths to defend your delusions but really, stop!! LOL, please stop!!! -you're breaking me up here! ROFLMAO!!!! bwaaahaaaahaaaahaaa FRBRBBBRBBBRRBBBBBP!!! (OH GEEEEZE, NOW YOU'VE GONE AND MADE ME FART!)

        Strong Sell would be too harsh. They need to have a Sentiment that says "OVERPRICED"!

        Sentiment: Sell

    • Come back when you've bought at $6 per share. Until then, you're just another bag of hot air that isn't getting his way.

      Oh I'm sure one of your aliases will claim to have gone long at $12 when the stock is trading at $20+. It's just the nature of a jealous sqnm puke such as yourself. After all, you were crying this same garbage when the stock was $6 and when sqnm was $29(with no revenue and no FDA test in sight) it certainly wasn't overpriced to you and your boyfriends now was it.

      Sentiment: Strong Buy

      • 1 Reply to mstevens19600
      • Wait a minute! Aren't YOU Mstevens? The same PUKE that sold out of his EXAS at 9.00 per share and told us she was going to buy "real estate" or somthing or the other, but you couldn't resist the temptation and got violated by a very bad man when following him into an ill timed and unfortunate foray into BPAX? Oh yes, lol, now I remember. THAT WAS YOU!!!. you have room to bash and talk about the imaginary investments of others!! How bout you take a couple of large spoonfuls of #$%$? Apparently the BPAX isn't working for you. Have you thought about an alternative medication? LOLOLOL!!

        Sentiment: Sell

 
EXAS
19.165+0.005(+0.03%)Sep 19 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.